These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 32408351)
1. Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Benoist GE; van Oort IM; Boerrigter E; Verhaegh GW; van Hooij O; Groen L; Smit F; de Mol P; Hamberg P; Dezentjé VO; Mehra N; Gerritsen W; Somford DM; van Erp NPH; Schalken JA Clin Chem; 2020 Jun; 66(6):842-851. PubMed ID: 32408351 [TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. Boerrigter E; Benoist GE; van Oort IM; Verhaegh GW; van Hooij O; Groen L; Smit F; Oving IM; de Mol P; Smilde TJ; Somford DM; Mehra N; Schalken JA; van Erp NP Mol Oncol; 2021 Sep; 15(9):2453-2465. PubMed ID: 33650292 [TBL] [Abstract][Full Text] [Related]
3. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110 [TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193 [TBL] [Abstract][Full Text] [Related]
5. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Huang X; Yuan T; Liang M; Du M; Xia S; Dittmar R; Wang D; See W; Costello BA; Quevedo F; Tan W; Nandy D; Bevan GH; Longenbach S; Sun Z; Lu Y; Wang T; Thibodeau SN; Boardman L; Kohli M; Wang L Eur Urol; 2015 Jan; 67(1):33-41. PubMed ID: 25129854 [TBL] [Abstract][Full Text] [Related]
6. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425 [TBL] [Abstract][Full Text] [Related]
7. Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. Maughan BL; Luber B; Nadal R; Antonarakis ES Prostate; 2017 Jan; 77(1):33-40. PubMed ID: 27527643 [TBL] [Abstract][Full Text] [Related]
8. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. Conteduca V; Burgio SL; Menna C; Carretta E; Rossi L; Bianchi E; Masini C; Amadori D; De Giorgi U Prostate; 2014 Dec; 74(16):1691-6. PubMed ID: 25262981 [TBL] [Abstract][Full Text] [Related]
9. Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. Zedan AH; Osther PJS; Assenholt J; Madsen JS; Hansen TF Sci Rep; 2020 Jan; 10(1):227. PubMed ID: 31937854 [TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304 [TBL] [Abstract][Full Text] [Related]
11. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. Fuerea A; Baciarello G; Patrikidou A; Albigès L; Massard C; Di Palma M; Escudier B; Fizazi K; Loriot Y Eur J Cancer; 2016 Jul; 61():44-51. PubMed ID: 27151554 [TBL] [Abstract][Full Text] [Related]
12. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263 [TBL] [Abstract][Full Text] [Related]
13. Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide. Takemura K; Ito M; Nakanishi Y; Kataoka M; Sakamoto K; Suzuki H; Tobisu KI; Koga F Anticancer Res; 2019 Oct; 39(10):5773-5780. PubMed ID: 31570481 [TBL] [Abstract][Full Text] [Related]
14. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer. Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643 [TBL] [Abstract][Full Text] [Related]
15. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820 [TBL] [Abstract][Full Text] [Related]
16. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study). Iguchi T; Tamada S; Kato M; Yasuda S; Yamasaki T; Nakatani T BMC Cancer; 2019 Apr; 19(1):339. PubMed ID: 30971225 [TBL] [Abstract][Full Text] [Related]
18. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623 [TBL] [Abstract][Full Text] [Related]
19. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380 [TBL] [Abstract][Full Text] [Related]
20. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]